Physician profile
Margaret E Simpson
NPI 1225081664
$2,497.43
in general payments reported to CMS, 2019-2025
24 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $193 · 2023: $785 · 2024: $1,040 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $428.08 | 2022-2025 | Vraylar |
| Novo Nordisk INC | $408.10 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $378.86 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $191.23 | 2023-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals Lp | $145.51 | 2024-2025 | Airsupra, Farxiga, Lokelma |
| Pfizer INC. | $130.84 | 2023-2025 | |
| Exact Sciences Corporation | $119.95 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $116.93 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $76.57 | 2022-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.37 | 2023-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.47 | 2022-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $56.41 | 2023 | Rexulti, Nuedexta |
| Amgen INC. | $48.42 | 2022-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $42.48 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $41.56 | 2023 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.27 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $28.73 | 2024 | Gemtesa |
| Dexcom, INC. | $24.12 | 2023 | Dexcom G6 Transmitter |
| Shionogi INC | $20.82 | 2022 | |
| Esperion Therapeutics, INC. | $18.60 | 2025 | Nexletol |
| Corium, LLC | $16.93 | 2023 | Adlarity |
| Sanofi-Aventis U.S. LLC | $15.33 | 2022 | |
| Irhythm Technologies, INC. | $15.10 | 2024 | Zio Xt Patch, Zio Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $13.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.